Bit Bio
Latest round
- Series D
Last raised
- Nov 2026
Total raised
- $255M
Investors
- 13
About Bit Bio
, based in the UK, is a biomedical company focused on synthetic biology solutions, particularly specializing in engineered human induced pluripotent stem cells for research and therapeutic applications. Bit Bio Ltd. operates in the field of synthetic biology, developing precision-engineered human cells. Founded in 2016 in Cambridge, UK, the company was established by Mark Kotter. Bit Bio Ltd specializes in the development and production of synthetic biology solutions, particularly through their flagship product, ioCells, which consists of deterministically programmed human induced pluripotent stem cell (iPSC)-derived cells. These cells are engineered for precision and consistency, enabling them to serve various applications in research and drug discovery. The company also offers a range of specialized cells, including ioDisease Model Cells designed for specific conditions like Alzheimer's disease and ALS, and CRISPR-ready ioCells, facilitating advanced genomic interventions. Bit Bio targets a diverse client base, including academic institutions, biopharmaceutical companies, and research organizations globally, particularly in the United States, Europe, and Asia, where there is a strong demand for innovative cell-based therapies and research tools. Bit Bio generates revenue through direct sales of its specialized cell products and services to institutional clients, including research facilities and pharmaceutical companies.40. The transaction structure primarily involves business-to-business (B2B) interactions, where clients place orders for specific cell types or custom solutions tailored to their research needs. The company plans to launch new products that enhance its offerings in the near future, while expanding its market presence specifically targeting North America, Europe, and Asia by 2025. In December 2025, Bit Bio Ltd.
Who invested in Bit Bio
13 investors across 5 rounds
See all investors in Bit Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bit Bio
Who invested in Bit Bio?
Bit Bio has 13 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bit Bio raised?
Bit Bio has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Bit Bio last raise money?
Bit Bio's most recent round on record is a Series D, in Nov 2026.
What does Bit Bio do?
, based in the UK, is a biomedical company focused on synthetic biology solutions, particularly specializing in engineered human induced pluripotent stem cells for research and therapeutic applications.
Where is Bit Bio headquartered?
Bit Bio is headquartered in Cambridge, UK.
Which VCs invest in companies like Bit Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Bit Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Bit Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.